Genticel Reports Final Results of GTL001 Phase 2 Trial in HPV16/18-Infected Women
December 13, 2016 12:30 ET
|
Genticel S.A.
No statistical difference in viral clearance between treatment and placebo groups at any time point over 2 yearsNo difference in incidence of subjects progressing to high-grade cervical lesions...
GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
November 30, 2016 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Appoints Eumedix as Strategic Advisor to Support Company’s Access to Innovative Drug Candidates
July 06, 2016 12:35 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, July 06, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women
June 23, 2016 11:45 ET
|
Genticel S.A.
No statistical difference seen between treatment and placebo GTL001 development plan is under review Strategic pipeline development activities remain on trackAgreement with Serum Institute of India on...
Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria
June 15, 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001
June 13, 2016 16:01 ET
|
Genticel S.A.
Ability to Use Clinically Validated hpv testsFive-Year Stability of GTL001 Drug Product PARIS and TOULOUSE, France, June 13, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels:...
Genticel Announces Publication in ‘Clinical Cancer Research’ of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001
June 01, 2016 13:10 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 01, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
April 20, 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, April 20, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces 2015 Annual Results and Strategic Update for 2016
March 14, 2016 09:21 ET
|
Genticel S.A.
Cash position of € 21.8 million as at December 31, 2015First income from partnership with Serum Institute of India Ltd recorded in 2015Operating expenses in line with 2015 clinical milestonesStrategic...
Genticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
January 27, 2016 13:22 ET
|
Genticel S.A.
12- month primary endpoint not met in the overall populationStatistical difference in viral clearance rates in 2 predefined key subgroups DSMB recommends continuation of the study per protocol18-month...